Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
20630 | 451 | 23.0 | 51% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
275 | 3 | NSAIDS//CYCLOOXYGENASE//CYCLOOXYGENASE 2 | 43399 |
466 | 2 | NSAIDS//NON STEROIDAL ANTI INFLAMMATORY DRUGS//COX 2 INHIBITORS | 15930 |
20630 | 1 | NABUMETONE//6 METHOXY 2 NAPHTHYLACETIC ACID//NAPROXEN | 451 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | NABUMETONE | authKW | 1794741 | 12% | 49% | 54 |
2 | 6 METHOXY 2 NAPHTHYLACETIC ACID | authKW | 498551 | 2% | 82% | 9 |
3 | NAPROXEN | authKW | 289056 | 14% | 7% | 64 |
4 | CAS 26159 34 2 | authKW | 203115 | 1% | 100% | 3 |
5 | 6MNA | authKW | 135410 | 0% | 100% | 2 |
6 | APRENINR | authKW | 135410 | 0% | 100% | 2 |
7 | CAS 104124 26 7 | authKW | 135410 | 0% | 100% | 2 |
8 | LIQUID CAPSULES | authKW | 135410 | 0% | 100% | 2 |
9 | S NAPROXEN BETAINATE SODIUM SALT MONOHYDRATE | authKW | 135410 | 0% | 100% | 2 |
10 | NAPROXEN DETERMINATION | authKW | 121866 | 1% | 60% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 2621 | 45% | 0% | 202 |
2 | Rheumatology | 2431 | 14% | 0% | 61 |
3 | Chemistry, Analytical | 845 | 20% | 0% | 88 |
4 | Medicine, General & Internal | 302 | 13% | 0% | 60 |
5 | Toxicology | 139 | 6% | 0% | 27 |
6 | Medicine, Research & Experimental | 125 | 7% | 0% | 33 |
7 | Biochemical Research Methods | 114 | 6% | 0% | 28 |
8 | Chemistry, Medicinal | 40 | 4% | 0% | 16 |
9 | Electrochemistry | 11 | 2% | 0% | 9 |
10 | Geriatrics & Gerontology | 6 | 1% | 0% | 4 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ETH DRUGS | 67705 | 0% | 100% | 1 |
2 | OUTCOMES W2E 50 | 67705 | 0% | 100% | 1 |
3 | PDEA | 67705 | 0% | 100% | 1 |
4 | RUMENT DEV OURCES | 67705 | 0% | 100% | 1 |
5 | SHOUNAN HIRATUKA PHARM | 67705 | 0% | 100% | 1 |
6 | ACCELERA UNIT | 33851 | 0% | 50% | 1 |
7 | CABRINI HOSP PUBL HLTH PREVENT MED | 33851 | 0% | 50% | 1 |
8 | ESTUDIOS CIENT CLIN PHARMA | 33851 | 0% | 50% | 1 |
9 | INTERNAL MED RHEUMATOL MED | 22567 | 0% | 33% | 1 |
10 | POND ST | 22567 | 0% | 33% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | REVISTA BRASILEIRA DE MEDICINA | 33839 | 2% | 7% | 7 |
2 | EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION | 15222 | 1% | 4% | 6 |
3 | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 5005 | 4% | 0% | 17 |
4 | DRUGS | 4811 | 4% | 0% | 20 |
5 | RHEUMATOLOGY AND REHABILITATION | 4681 | 1% | 2% | 3 |
6 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 4067 | 4% | 0% | 17 |
7 | PHARMATHERAPEUTICA | 3431 | 1% | 1% | 4 |
8 | AMERICAN JOURNAL OF MEDICINE | 3183 | 5% | 0% | 23 |
9 | INVESTIGACION MEDICA INTERNACIONAL | 3039 | 0% | 2% | 2 |
10 | BAILLIERES CLINICAL RHEUMATOLOGY | 2399 | 1% | 1% | 4 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | NABUMETONE | 1794741 | 12% | 49% | 54 | Search NABUMETONE | Search NABUMETONE |
2 | 6 METHOXY 2 NAPHTHYLACETIC ACID | 498551 | 2% | 82% | 9 | Search 6+METHOXY+2+NAPHTHYLACETIC+ACID | Search 6+METHOXY+2+NAPHTHYLACETIC+ACID |
3 | NAPROXEN | 289056 | 14% | 7% | 64 | Search NAPROXEN | Search NAPROXEN |
4 | CAS 26159 34 2 | 203115 | 1% | 100% | 3 | Search CAS+26159+34+2 | Search CAS+26159+34+2 |
5 | 6MNA | 135410 | 0% | 100% | 2 | Search 6MNA | Search 6MNA |
6 | APRENINR | 135410 | 0% | 100% | 2 | Search APRENINR | Search APRENINR |
7 | CAS 104124 26 7 | 135410 | 0% | 100% | 2 | Search CAS+104124+26+7 | Search CAS+104124+26+7 |
8 | LIQUID CAPSULES | 135410 | 0% | 100% | 2 | Search LIQUID+CAPSULES | Search LIQUID+CAPSULES |
9 | S NAPROXEN BETAINATE SODIUM SALT MONOHYDRATE | 135410 | 0% | 100% | 2 | Search S+NAPROXEN+BETAINATE+SODIUM+SALT+MONOHYDRATE | Search S+NAPROXEN+BETAINATE+SODIUM+SALT+MONOHYDRATE |
10 | NAPROXEN DETERMINATION | 121866 | 1% | 60% | 3 | Search NAPROXEN+DETERMINATION | Search NAPROXEN+DETERMINATION |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | FRIEDEL, HA , TODD, PA , (1988) NABUMETONE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES.DRUGS. VOL. 35. ISSUE 5. P. 504-524 | 40 | 100% | 36 |
2 | FRIEDEL, HA , LANGTRY, HD , BUCKLEY, MM , (1993) NABUMETONE - A REAPPRAISAL OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN RHEUMATIC DISEASES.DRUGS. VOL. 45. ISSUE 1. P. 131-156 | 35 | 80% | 38 |
3 | ELSINGHORST, PW , KINZIG, M , RODAMER, M , HOLZGRABE, U , SORGEL, F , (2011) AN LC-MS/MS PROCEDURE FOR THE QUANTIFICATION OF NAPROXEN IN HUMAN PLASMA: DEVELOPMENT, VALIDATION, COMPARISON WITH OTHER METHODS, AND APPLICATION TO A PHARMACOKINETIC STUDY.JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. VOL. 879. ISSUE 19. P. 1686 -1696 | 27 | 53% | 19 |
4 | ALIZADEH, N , KEYHANIAN, F , (2015) SIMPLE, SENSITIVE AND SELECTIVE SPECTROPHOTOMETRIC ASSAY OF NAPROXEN IN PURE, PHARMACEUTICAL PREPARATION AND HUMAN SERUM SAMPLES.ACTA POLONIAE PHARMACEUTICA. VOL. 72. ISSUE 5. P. 867 -875 | 18 | 69% | 0 |
5 | DAVIES, NM , ANDERSON, KE , (1997) CLINICAL PHARMACOKINETICS OF NAPROXEN.CLINICAL PHARMACOKINETICS. VOL. 32. ISSUE 4. P. 268-293 | 39 | 44% | 50 |
6 | TODD, PA , CLISSOLD, SP , (1990) NAPROXEN - A REAPPRAISAL OF ITS PHARMACOLOGY, AND THERAPEUTIC USE IN RHEUMATIC DISEASES AND PAIN STATES.DRUGS. VOL. 40. ISSUE 1. P. 91-137 | 71 | 26% | 116 |
7 | NOBILIS, M , MIKUSEK, J , SZOTAKOVA, B , JIRASKO, R , HOLCAPEK, M , CHAMSEDDIN, C , JIRA, T , KUCERA, R , KUNES, J , POUR, M , (2013) ANALYTICAL POWER OF LLE-HPLC-PDA-MS/MS IN DRUG METABOLISM STUDIES: IDENTIFICATION OF NEW NABUMETONE METABOLITES.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. VOL. 80. ISSUE . P. 164-172 | 14 | 70% | 6 |
8 | SOMA, LR , UBOH, CE , RUDY, JA , SMITH, MS , (1996) DISPOSITION AND EXCRETION OF 6-METHOXY-2-NAPHTHYLACETIC ACID, THE ACTIVE METABOLITE OF NABUMETONE IN HORSES.AMERICAN JOURNAL OF VETERINARY RESEARCH. VOL. 57. ISSUE 4. P. 517-521 | 20 | 83% | 4 |
9 | NOBILIS, M , KOPECKY, J , KVETINA, J , SVOBODA, Z , POUR, M , KUNES, J , HOLCAPEK, M , KOLAROVA, L , (2003) COMPARATIVE BIOTRANSFORMATION AND DISPOSITION STUDIES OF NABUMETONE IN HUMANS AND MINIPIGS USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH ULTRAVIOLET, FLUORESCENCE AND MASS SPECTROMETRIC DETECTION.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. VOL. 32. ISSUE 4-5. P. 641-656 | 14 | 88% | 34 |
10 | SVETLIK, S , STICHA, M , MATOUSKOVA, O , NESPESNA, L , SKLENAR, Z , BARTUNEK, A , PERLIK, F , SLANAR, O , (2016) NABUMETONE AND 6-MNA PHARMACOKINETICS, ASSESSMENT OF INTRASUBJECT VARIABILITY AND GENDER EFFECT.AMERICAN JOURNAL OF THERAPEUTICS. VOL. 23. ISSUE 6. P. E1498 -E1503 | 12 | 75% | 0 |
Classes with closest relation at Level 1 |